Age 0 3 0 3 B-age
> 4 5 4 5 O
18 5 7 5 7 B-lower_bound
years 8 13 8 13 I-lower_bound

All 0 3 14 17 O
adenocarcinoma 4 18 18 32 B-cancer
patients 19 27 33 41 O
will 28 32 42 46 O
be 33 35 47 49 O
tested 36 42 50 56 O
for 43 46 57 60 O
ALK 47 50 61 64 B-treatment
rearrangements 51 65 65 79 I-treatment
and 66 69 80 83 O
EGFR 70 74 84 88 B-treatment
( 75 76 89 90 O
Exon 76 80 90 94 O
19 81 83 95 97 O
Deletion 84 92 98 106 O
and 93 96 107 110 O
Exon 97 101 111 115 O
21 102 104 116 118 O
L8585R 105 111 119 125 O
Substitution 112 124 126 138 O
) 124 125 138 139 O
mutations 126 135 140 149 O
and 136 139 150 153 O
must 140 144 154 158 O
have 145 149 159 163 O
been 150 154 164 168 O
treated 155 162 169 176 O
with 163 167 177 181 O
prior 168 173 182 187 B-treatment
EGFR 174 178 188 192 I-treatment
or 179 181 193 195 O
ALK 182 185 196 199 B-treatment
therapy 186 193 200 207 I-treatment
as 194 196 208 210 O
well 197 201 211 215 O
as 202 204 216 218 O
a 205 206 219 220 O
platinum 207 215 221 229 O
containing 216 226 230 240 O
doublet 227 234 241 248 O

Any 0 3 249 252 O
active 4 10 253 259 O
history 11 18 260 267 O
of 19 21 268 270 O
a 22 23 271 272 O
known 24 29 273 278 O
autoimmune 30 40 279 289 B-chronic_disease
disease 41 48 290 297 I-chronic_disease

Because 0 7 298 305 O
no 8 10 306 308 O
dosing 11 17 309 315 O
or 18 20 316 318 O
adverse 21 28 319 326 O
event 29 34 327 332 O
data 35 39 333 337 O
are 40 43 338 341 O
currently 44 53 342 351 O
available 54 63 352 361 O
on 64 66 362 364 O
the 67 70 365 368 O
use 71 74 369 372 O
of 75 77 373 375 O
azacitidine 78 89 376 387 B-treatment
with 90 94 388 392 O
entinostat 95 105 393 403 B-treatment
, 105 106 403 404 O
or 107 109 405 407 O
of 110 112 408 410 O
Nivolumab 113 122 411 420 B-treatment
, 122 123 420 421 O
in 124 126 422 424 O
patients 127 135 425 433 O
< 136 137 434 435 O
18 137 139 435 437 B-upper_bound
years 140 145 438 443 I-upper_bound
of 146 148 444 446 O
age 149 152 447 450 B-age
, 152 153 450 451 O
children 154 162 452 460 O
are 163 166 461 464 O
excluded 167 175 465 473 O
from 176 180 474 478 O
this 181 185 479 483 O
study 186 191 484 489 O

Because 0 7 490 497 O
there 8 13 498 503 O
is 14 16 504 506 O
an 17 19 507 509 O
unknown 20 27 510 517 O
but 28 31 518 521 O
potential 32 41 522 531 O
risk 42 46 532 536 O
for 47 50 537 540 O
adverse 51 58 541 548 O
events 59 65 549 555 O
in 66 68 556 558 O
nursing 69 76 559 566 O
infants 77 84 567 574 O
secondary 85 94 575 584 O
to 95 97 585 587 O
treatment 98 107 588 597 B-treatment
of 108 110 598 600 O
the 111 114 601 604 O
mother 115 121 605 611 O
with 122 126 612 616 O
entinostat 127 137 617 627 B-treatment
, 137 138 627 628 O
azacitidine 139 150 629 640 B-treatment
, 150 151 640 641 O
or 152 154 642 644 O
Nivolumab 155 164 645 654 B-treatment
breastfeeding 165 178 655 668 O
should 179 185 669 675 O
be 186 188 676 678 O
discontinued 189 201 679 691 O
if 202 204 692 694 O
the 205 208 695 698 O
mother 209 215 699 705 O
is 216 218 706 708 O
treated 219 226 709 716 O
on 227 229 717 719 O
this 230 234 720 724 O
protocol 235 243 725 733 O

Eastern 0 7 734 741 B-clinical_variable
Cooperative 8 19 742 753 I-clinical_variable
Oncology 20 28 754 762 I-clinical_variable
Group 29 34 763 768 I-clinical_variable
( 35 36 769 770 I-clinical_variable
ECOG 36 40 770 774 I-clinical_variable
) 40 41 774 775 I-clinical_variable
performance 42 53 776 787 I-clinical_variable
status 54 60 788 794 I-clinical_variable
0 61 62 795 796 B-lower_bound
to 63 65 797 799 O
1 66 67 800 801 B-upper_bound

For 0 3 802 805 O
this 4 8 806 810 O
reason 9 15 811 817 O
women 16 21 818 823 B-gender
of 22 24 824 826 O
child 25 30 827 832 O
- 30 31 832 833 O
bearing 31 38 833 840 O
potential 39 48 841 850 O
and 49 52 851 854 O
men 53 56 855 858 O
must 57 61 859 863 O
agree 62 67 864 869 B-contraception_consent
to 68 70 870 872 I-contraception_consent
use 71 74 873 876 I-contraception_consent
adequate 75 83 877 885 I-contraception_consent
contraception 84 97 886 899 I-contraception_consent
( 98 99 900 901 O
hormonal 99 107 901 909 B-contraception_consent
or 108 110 910 912 O
barrier 111 118 913 920 B-contraception_consent
method 119 125 921 927 I-contraception_consent
of 126 128 928 930 I-contraception_consent
birth 129 134 931 936 I-contraception_consent
control 135 142 937 944 I-contraception_consent
; 142 143 944 945 O
abstinence 144 154 946 956 B-contraception_consent
) 154 155 956 957 O
prior 156 161 958 963 O
to 162 164 964 966 O
study 165 170 967 972 O
entry 171 176 973 978 O
and 177 180 979 982 O
for 181 184 983 986 O
the 185 188 987 990 O
duration 189 197 991 999 O
of 198 200 1000 1002 O
study 201 206 1003 1008 O
participation 207 220 1009 1022 O
and 221 224 1023 1026 O
for 225 228 1027 1030 O
up 229 231 1031 1033 O
to 232 234 1034 1036 O
23 235 237 1037 1039 B-upper_bound
weeks 238 243 1040 1045 I-upper_bound
after 244 249 1046 1051 I-upper_bound
the 250 253 1052 1055 O
last 254 258 1056 1060 O
dose 259 263 1061 1065 O
of 264 266 1066 1068 O
nivolumab 267 276 1069 1078 B-treatment

HIV 0 3 1079 1082 B-chronic_disease
- 3 4 1082 1083 O
positive 4 12 1083 1091 O
patients 13 21 1092 1100 O
are 22 25 1101 1104 O
excluded 26 34 1105 1113 O

History 0 7 1114 1121 O
of 8 10 1122 1124 O
allergic 11 19 1125 1133 O
reactions 20 29 1134 1143 O
attributed 30 40 1144 1154 O
to 41 43 1155 1157 O
compounds 44 53 1158 1167 O
of 54 56 1168 1170 O
similar 57 64 1171 1178 O
chemical 65 73 1179 1187 O
or 74 76 1188 1190 O
biologic 77 85 1191 1199 O
composition 86 97 1200 1211 O
to 98 100 1212 1214 O
entinostat 101 111 1215 1225 B-allergy_name
, 111 112 1225 1226 O
azacitidine 113 124 1227 1238 B-allergy_name
, 124 125 1238 1239 O
or 126 128 1240 1242 O
Nivolumab 129 138 1243 1252 B-allergy_name

Inhaled 0 7 1253 1260 B-treatment
or 8 10 1261 1263 O
topical 11 18 1264 1271 B-treatment
steroids 19 27 1272 1280 I-treatment
and 28 31 1281 1284 O
adrenal 32 39 1285 1292 O
replacement 40 51 1293 1304 B-treatment
steroid 52 59 1305 1312 I-treatment
doses 60 65 1313 1318 O
> 66 67 1319 1320 O
10 68 70 1321 1323 B-lower_bound
mg 71 73 1324 1326 I-lower_bound
daily 74 79 1327 1332 O
prednisone 80 90 1333 1343 B-treatment
equivalent 91 101 1344 1354 O
, 101 102 1354 1355 O
are 103 106 1356 1359 O
permitted 107 116 1360 1369 O
in 117 119 1370 1372 O
the 120 123 1373 1376 O
absence 124 131 1377 1384 O
of 132 134 1385 1387 O
active 135 141 1388 1394 O
autoimmune 142 152 1395 1405 B-chronic_disease
disease 153 160 1406 1413 I-chronic_disease

Known 0 5 1414 1419 O
or 6 8 1420 1422 O
suspected 9 18 1423 1432 O
hypersensitivity 19 35 1433 1449 O
to 36 38 1450 1452 O
azacitidine 39 50 1453 1464 B-allergy_name
or 51 53 1465 1467 O
mannitol 54 62 1468 1476 B-allergy_name

Life 0 4 1477 1481 B-clinical_variable
expectancy 5 15 1482 1492 I-clinical_variable
of 16 18 1493 1495 O
greater 19 26 1496 1503 O
than 27 31 1504 1508 O
12 32 34 1509 1511 B-lower_bound
weeks 35 40 1512 1517 I-lower_bound

Men 0 3 1518 1521 B-gender
who 4 7 1522 1525 O
are 8 11 1526 1529 O
sexually 12 20 1530 1538 O
active 21 27 1539 1545 O
with 28 32 1546 1550 O
women 33 38 1551 1556 B-gender
of 39 41 1557 1559 O
childbearing 42 54 1560 1572 O
potential 55 64 1573 1582 O
must 65 69 1583 1587 O
also 70 74 1588 1592 O
use 75 78 1593 1596 B-contraception_consent
an 79 81 1597 1599 I-contraception_consent
adequate 82 90 1600 1608 I-contraception_consent
contraceptive 91 104 1609 1622 I-contraception_consent
method 105 111 1623 1629 I-contraception_consent
for 112 115 1630 1633 O
up 116 118 1634 1636 O
to 119 121 1637 1639 O
31 122 124 1640 1642 B-upper_bound
weeks 125 130 1643 1648 I-upper_bound
after 131 136 1649 1654 O
fhe 137 140 1655 1658 O
last 141 145 1659 1663 O
dose 146 150 1664 1668 O
of 151 153 1669 1671 O
nivolumab 154 163 1672 1681 B-treatment

Patients 0 8 1682 1690 O
must 9 13 1691 1695 O
be 14 16 1696 1698 O
willing 17 24 1699 1706 O
to 25 27 1707 1709 O
undergo 28 35 1710 1717 O
a 36 37 1718 1719 O
pre 38 41 1720 1723 B-treatment
- 41 42 1723 1724 I-treatment
treatment 42 51 1724 1733 I-treatment
biopsy 52 58 1734 1740 I-treatment
, 58 59 1740 1741 O
either 60 66 1742 1748 O
core 67 71 1749 1753 B-treatment
needle 72 78 1754 1760 I-treatment
biopsy 79 85 1761 1767 I-treatment
or 86 88 1768 1770 O
equivalent 89 99 1771 1781 O
amount 100 106 1782 1788 O
or 107 109 1789 1791 O
via 110 113 1792 1795 O
excisional 114 124 1796 1806 B-treatment
specimen 125 133 1807 1815 I-treatment

Patients 0 8 1816 1824 O
must 9 13 1825 1829 O
have 14 18 1830 1834 O
disease 19 26 1835 1842 O
amenable 27 35 1843 1851 O
to 36 38 1852 1854 O
biopsy 39 45 1855 1861 B-treatment
at 46 48 1862 1864 O
the 49 52 1865 1868 O
time 53 57 1869 1873 O
of 58 60 1874 1876 O
enrollment 61 71 1877 1887 O
as 72 74 1888 1890 O
biopsies 75 83 1891 1899 B-treatment
are 84 87 1900 1903 O
required 88 96 1904 1912 O
for 97 100 1913 1916 O
study 101 106 1917 1922 O
participation 107 120 1923 1936 O

Patients 0 8 1937 1945 O
must 9 13 1946 1950 O
have 14 18 1951 1955 O
histologically 19 33 1956 1970 O
proven 34 40 1971 1977 O
stage 41 46 1978 1983 B-cancer
IIIB 47 51 1984 1988 I-cancer
, 51 52 1988 1989 O
IV 53 55 1990 1992 B-cancer
or 56 58 1993 1995 O
recurrent 59 68 1996 2005 O
non 69 72 2006 2009 B-cancer
- 72 73 2009 2010 I-cancer
small 73 78 2010 2015 I-cancer
cell 79 83 2016 2020 I-cancer
lung 84 88 2021 2025 I-cancer
cancer 89 95 2026 2032 I-cancer

Patients 0 8 2033 2041 O
must 9 13 2042 2046 O
have 14 18 2047 2051 O
measurable 19 29 2052 2062 O
disease 30 37 2063 2070 O
, 37 38 2070 2071 O
defined 39 46 2072 2079 O
as 47 49 2080 2082 O
at 50 52 2083 2085 O
least 53 58 2086 2091 O
one 59 62 2092 2095 B-lower_bound
lesion 63 69 2096 2102 O
that 70 74 2103 2107 O
can 75 78 2108 2111 O
be 79 81 2112 2114 O
accurately 82 92 2115 2125 O
measured 93 101 2126 2134 O
in 102 104 2135 2137 O
at 105 107 2138 2140 O
least 108 113 2141 2146 O
one 114 117 2147 2150 O
dimension 118 127 2151 2160 O
( 128 129 2161 2162 O
longest 129 136 2162 2169 O
diameter 137 145 2170 2178 O
to 146 148 2179 2181 O
be 149 151 2182 2184 O
recorded 152 160 2185 2193 O
for 161 164 2194 2197 O
non 165 168 2198 2201 O
- 168 169 2201 2202 O
nodal 169 174 2202 2207 O
lesions 175 182 2208 2215 O
and 183 186 2216 2219 O
short 187 192 2220 2225 O
axis 193 197 2226 2230 O
for 198 201 2231 2234 O
nodal 202 207 2235 2240 O
lesions 208 215 2241 2248 O
) 215 216 2248 2249 O
as 217 219 2250 2252 O
> 220 221 2253 2254 O
20 221 223 2254 2256 B-lower_bound
mm 224 226 2257 2259 I-lower_bound
with 227 231 2260 2264 O
conventional 232 244 2265 2277 O
techniques 245 255 2278 2288 O
or 256 258 2289 2291 O
as 259 261 2292 2294 O
> 262 263 2295 2296 O
10 263 265 2296 2298 B-lower_bound
mm 266 268 2299 2301 I-lower_bound
with 269 273 2302 2306 O
spiral 274 280 2307 2313 B-treatment
CT 281 283 2314 2316 I-treatment
scan 284 288 2317 2321 I-treatment
, 288 289 2321 2322 O
MRI 290 293 2323 2326 B-treatment
, 293 294 2326 2327 O
or 295 297 2328 2330 O
calipers 298 306 2331 2339 B-treatment
by 307 309 2340 2342 I-treatment
clinical 310 318 2343 2351 I-treatment
exam 319 323 2352 2356 I-treatment

Patients 0 8 2357 2365 O
must 9 13 2366 2370 O
have 14 18 2371 2375 O
received 19 27 2376 2384 O
at 28 30 2385 2387 O
least 31 36 2388 2393 O
one 37 40 2394 2397 B-lower_bound
platinum 41 49 2398 2406 O
based 50 55 2407 2412 O
chemotherapy 56 68 2413 2425 B-treatment
, 68 69 2425 2426 O
and 70 73 2427 2430 O
not 74 77 2431 2434 O
more 78 82 2435 2439 O
than 83 87 2440 2444 O
three 88 93 2445 2450 B-upper_bound
, 93 94 2450 2451 O
prior 95 100 2452 2457 O
therapies 101 110 2458 2467 B-treatment
for 111 114 2468 2471 O
stage 115 120 2472 2477 B-cancer
IIIB 121 125 2478 2482 I-cancer
/ 125 126 2482 2483 I-cancer
IV 126 128 2483 2485 I-cancer
disease 129 136 2486 2493 I-cancer

Patients 0 8 2494 2502 O
requiring 9 18 2503 2512 O
continuous 19 29 2513 2523 O
supplemental 30 42 2524 2536 B-treatment
oxygen 43 49 2537 2543 I-treatment
are 50 53 2544 2547 O
excluded 54 62 2548 2556 O
to 63 65 2557 2559 O
avoid 66 71 2560 2565 O
possible 72 80 2566 2574 O
complications 81 94 2575 2588 O
from 95 99 2589 2593 O
pneumonitis 100 111 2594 2605 B-chronic_disease

Patients 0 8 2606 2614 O
who 9 12 2615 2618 O
are 13 16 2619 2622 O
receiving 17 26 2623 2632 O
any 27 30 2633 2636 O
other 31 36 2637 2642 O
anticancer 37 47 2643 2653 B-treatment
therapy 48 55 2654 2661 I-treatment

Patients 0 8 2662 2670 O
who 9 12 2671 2674 O
have 13 17 2675 2679 O
had 18 21 2680 2683 O
chemotherapy 22 34 2684 2696 B-treatment
or 35 37 2697 2699 O
radiotherapy 38 50 2700 2712 B-treatment
within 51 57 2713 2719 O
2 58 59 2720 2721 O
weeks 60 65 2722 2727 O
( 66 67 2728 2729 O
6 67 68 2729 2730 B-upper_bound
weeks 69 74 2731 2736 I-upper_bound
for 75 78 2737 2740 O
nitrosoureas 79 91 2741 2753 B-treatment
or 92 94 2754 2756 O
mitomycin 95 104 2757 2766 B-treatment
C 105 106 2767 2768 I-treatment
) 106 107 2768 2769 O
prior 108 113 2770 2775 O
to 114 116 2776 2778 O
entering 117 125 2779 2787 O
the 126 129 2788 2791 O
study 130 135 2792 2797 O
or 136 138 2798 2800 O
those 139 144 2801 2806 O
who 145 148 2807 2810 O
have 149 153 2811 2815 O
not 154 157 2816 2819 O
recovered 158 167 2820 2829 O
from 168 172 2830 2834 O
adverse 173 180 2835 2842 O
events 181 187 2843 2849 O
due 188 191 2850 2853 O
to 192 194 2854 2856 O
agents 195 201 2857 2863 O
administered 202 214 2864 2876 O
more 215 219 2877 2881 O
than 220 224 2882 2886 O
2 225 226 2887 2888 O
weeks 227 232 2889 2894 O
earlier 233 240 2895 2902 O

Patients 0 8 2903 2911 O
who 9 12 2912 2915 O
received 13 21 2916 2924 O
adjuvant 22 30 2925 2933 B-treatment
or 31 33 2934 2936 I-treatment
neoadjuvant 34 45 2937 2948 I-treatment
platinum 46 54 2949 2957 I-treatment
- 54 55 2957 2958 I-treatment
doublet 55 62 2958 2965 I-treatment
chemotherapy 63 75 2966 2978 I-treatment
( 76 77 2979 2980 O
after 77 82 2980 2985 B-treatment
surgery 83 90 2986 2993 I-treatment
and/or 91 97 2994 3000 O
radiation 98 107 3001 3010 B-treatment
therapy 108 115 3011 3018 I-treatment
) 115 116 3018 3019 O
and 117 120 3020 3023 O
developed 121 130 3024 3033 O
recurrent 131 140 3034 3043 O
or 141 143 3044 3046 O
metastatic 144 154 3047 3057 B-cancer
disease 155 162 3058 3065 I-cancer
within 163 169 3066 3072 O
6 170 171 3073 3074 B-upper_bound
months 172 178 3075 3081 I-upper_bound
of 179 181 3082 3084 O
completing 182 192 3085 3095 O
therapy 193 200 3096 3103 O
are 201 204 3104 3107 O
eligible 205 213 3108 3116 O
and 214 217 3117 3120 O
the 218 221 3121 3124 O
adjuvant 222 230 3125 3133 B-treatment
or 231 233 3134 3136 I-treatment
neoadjuvant 234 245 3137 3148 I-treatment
chemotherapy 246 258 3149 3161 I-treatment
will 259 263 3162 3166 O
count 264 269 3167 3172 O
as 270 272 3173 3175 O
a 273 274 3176 3177 O
line 275 279 3178 3182 O
of 280 282 3183 3185 O
therapy 283 290 3186 3193 O
as 291 293 3194 3196 O
above 294 299 3197 3202 O

Patients 0 8 3203 3211 O
with 9 13 3212 3216 O
a 14 15 3217 3218 O
condition 16 25 3219 3228 O
requiring 26 35 3229 3238 O
systemic 36 44 3239 3247 B-treatment
treatment 45 54 3248 3257 I-treatment
with 55 59 3258 3262 O
either 60 66 3263 3269 O
corticosteroids 67 82 3270 3285 B-treatment
( 83 84 3286 3287 O
> 84 85 3287 3288 O
10 85 87 3288 3290 B-lower_bound
mg 88 90 3291 3293 I-lower_bound
daily 91 96 3294 3299 O
prednisone 97 107 3300 3310 B-treatment
equivalent 108 118 3311 3321 O
) 118 119 3321 3322 O
or 120 122 3323 3325 O
other 123 128 3326 3331 O
immunosuppressive 129 146 3332 3349 B-treatment
medications 147 158 3350 3361 I-treatment
within 159 165 3362 3368 O
14 166 168 3369 3371 B-upper_bound
days 169 173 3372 3376 I-upper_bound
of 174 176 3377 3379 O
randomization 177 190 3380 3393 O

Patients 0 8 3394 3402 O
with 9 13 3403 3407 O
a 14 15 3408 3409 O
history 16 23 3410 3417 O
of 24 26 3418 3420 O
carcinomatous 27 40 3421 3434 B-cancer
meningitis 41 51 3435 3445 I-cancer
are 52 55 3446 3449 O
not 56 59 3450 3453 O
eligible 60 68 3454 3462 O

Patients 0 8 3463 3471 O
with 9 13 3472 3476 O
active 14 20 3477 3483 B-chronic_disease
hepatitis 21 30 3484 3493 I-chronic_disease
B 31 32 3494 3495 I-chronic_disease
or 33 35 3496 3498 O
hepatitis 36 45 3499 3508 B-chronic_disease
C 46 47 3509 3510 I-chronic_disease
are 48 51 3511 3514 O
excluded 52 60 3515 3523 O

Patients 0 8 3524 3532 O
with 9 13 3533 3537 O
advanced 14 22 3538 3546 O
malignant 23 32 3547 3556 B-cancer
hepatic 33 40 3557 3564 I-cancer
tumors 41 47 3565 3571 I-cancer

Patients 0 8 3572 3580 O
with 9 13 3581 3585 O
brain 14 19 3586 3591 B-cancer
metastases 20 30 3592 3602 I-cancer
must 31 35 3603 3607 O
have 36 40 3608 3612 O
stable 41 47 3613 3619 O
neurologic 48 58 3620 3630 O
status 59 65 3631 3637 O
following 66 75 3638 3647 O
local 76 81 3648 3653 B-treatment
therapy 82 89 3654 3661 I-treatment
( 90 91 3662 3663 O
surgery 91 98 3663 3670 B-treatment
or 99 101 3671 3673 O
radiation 102 111 3674 3683 B-treatment
) 111 112 3683 3684 O
for 113 116 3685 3688 O
at 117 119 3689 3691 O
least 120 125 3692 3697 O
2 126 127 3698 3699 B-lower_bound
weeks 128 133 3700 3705 I-lower_bound
without 134 141 3706 3713 O
the 142 145 3714 3717 O
use 146 149 3718 3721 O
of 150 152 3722 3724 O
steroids 153 161 3725 3733 B-treatment
or 162 164 3734 3736 O
on 165 167 3737 3739 O
stable 168 174 3740 3746 O
or 175 177 3747 3749 O
decreasing 178 188 3750 3760 O
dose 189 193 3761 3765 O
of 194 196 3766 3768 O
< 197 198 3769 3770 O
10 199 201 3771 3773 B-upper_bound
mg 201 203 3773 3775 I-upper_bound
daily 204 209 3776 3781 O
prednisone 210 220 3782 3792 B-treatment
( 221 222 3793 3794 O
or 222 224 3794 3796 O
equivalent 225 235 3797 3807 O
) 235 236 3807 3808 O
, 236 237 3808 3809 O
and 238 241 3810 3813 O
must 242 246 3814 3818 O
be 247 249 3819 3821 O
without 250 257 3822 3829 O
neurologic 258 268 3830 3840 B-chronic_disease
dysfunction 269 280 3841 3852 I-chronic_disease
that 281 285 3853 3857 O
would 286 291 3858 3863 O
confound 292 300 3864 3872 O
the 301 304 3873 3876 O
evaluation 305 315 3877 3887 O
of 316 318 3888 3890 O
neurologic 319 329 3891 3901 O
and 330 333 3902 3905 O
other 334 339 3906 3911 O
adverse 340 347 3912 3919 O
events 348 354 3920 3926 O

Patients 0 8 3927 3935 O
with 9 13 3936 3940 O
documented 14 24 3941 3951 O
EGFR 25 29 3952 3956 B-clinical_variable
or 30 32 3957 3959 O
ALK 33 36 3960 3963 B-clinical_variable
mutations 37 46 3964 3973 O
must 47 51 3974 3978 O
have 52 56 3979 3983 O
been 57 61 3984 3988 O
treated 62 69 3989 3996 O
with 70 74 3997 4001 O
prior 75 80 4002 4007 B-treatment
EGFR 81 85 4008 4012 I-treatment
or 86 88 4013 4015 I-treatment
ALK 89 92 4016 4019 I-treatment
therapy 93 100 4020 4027 I-treatment
as 101 103 4028 4030 O
well 104 108 4031 4035 O
as 109 111 4036 4038 O
a 112 113 4039 4040 O
platinum 114 122 4041 4049 B-treatment
containing 123 133 4050 4060 I-treatment
doublet 134 141 4061 4068 I-treatment

Patients 0 8 4069 4077 O
with 9 13 4078 4082 O
malabsorption 14 27 4083 4096 B-chronic_disease
in 28 30 4097 4099 O
the 31 34 4100 4103 O
small 35 40 4104 4109 O
intestine 41 50 4110 4119 O
or 51 53 4120 4122 O
other 54 59 4123 4128 O
conditions 60 70 4129 4139 O
that 71 75 4140 4144 O
would 76 81 4145 4150 O
preclude 82 90 4151 4159 O
administration 91 105 4160 4174 O
of 106 108 4175 4177 O
oral 109 113 4178 4182 B-treatment
medication 114 124 4183 4193 I-treatment

Patients 0 8 4194 4202 O
with 9 13 4203 4207 O
uncontrolled 14 26 4208 4220 O
brain 27 32 4221 4226 B-cancer
metastases 33 43 4227 4237 I-cancer

Pregnant 0 8 4238 4246 B-pregnancy
women 9 14 4247 4252 B-gender
are 15 18 4253 4256 O
excluded 19 27 4257 4265 O
from 28 32 4266 4270 O
this 33 37 4271 4275 O
study 38 43 4276 4281 O
because 44 51 4282 4289 O
entinostat 52 62 4290 4300 B-treatment
, 62 63 4300 4301 O
azacitidine 64 75 4302 4313 B-treatment
, 75 76 4313 4314 O
and 77 80 4315 4318 O
Nivolumab 81 90 4319 4328 B-treatment
are 91 94 4329 4332 O
agents 95 101 4333 4339 O
with 102 106 4340 4344 O
the 107 110 4345 4348 O
potential 111 120 4349 4358 O
for 121 124 4359 4362 O
teratogenic 125 136 4363 4374 B-treatment
or 137 139 4375 4377 O
abortifacient 140 153 4378 4391 B-treatment
effects 154 161 4392 4399 O

Prior 0 5 4400 4405 B-treatment
therapy 6 13 4406 4413 I-treatment
with 14 18 4414 4418 I-treatment
anti 19 23 4419 4423 I-treatment
- 23 24 4423 4424 I-treatment
PD-1 24 28 4424 4428 I-treatment
, 28 29 4428 4429 O
anti 30 34 4430 4434 B-treatment
- 34 35 4434 4435 I-treatment
PD 35 37 4435 4437 I-treatment
- 37 38 4437 4438 I-treatment
L1 38 40 4438 4440 I-treatment
, 40 41 4440 4441 O
anti 42 46 4442 4446 B-treatment
- 46 47 4446 4447 I-treatment
PD 47 49 4447 4449 I-treatment
- 49 50 4449 4450 I-treatment
L2 50 52 4450 4452 I-treatment
, 52 53 4452 4453 O
anti 54 58 4454 4458 B-treatment
- 58 59 4458 4459 I-treatment
CD137 59 64 4459 4464 I-treatment
, 64 65 4464 4465 O
anti 66 70 4466 4470 B-treatment
- 70 71 4470 4471 I-treatment
CTLA-4 71 77 4471 4477 I-treatment
antibody 78 86 4478 4486 I-treatment
therapies 87 96 4487 4496 I-treatment
, 96 97 4496 4497 O
any 98 101 4498 4501 O
other 102 107 4502 4507 O
antibody 108 116 4508 4516 O
or 117 119 4517 4519 O
drug 120 124 4520 4524 O
specifically 125 137 4525 4537 O
targeting 138 147 4538 4547 O
T 148 149 4548 4549 O
- 149 150 4549 4550 O
cell 150 154 4550 4554 O
co 155 157 4555 4557 O
- 157 158 4557 4558 O
stimulation 158 169 4558 4569 O
or 170 172 4570 4572 O
checkpoint 173 183 4573 4583 O
pathways 184 192 4584 4592 O
, 192 193 4592 4593 O
DNA 194 197 4594 4597 B-treatment
methyltransferase 198 215 4598 4615 I-treatment
therapy 216 223 4616 4623 I-treatment
or 224 226 4624 4626 O
HDAC 227 231 4627 4631 B-treatment
inhibitor 232 241 4632 4641 I-treatment
therapy 242 249 4642 4649 I-treatment

Should 0 6 4650 4656 O
a 7 8 4657 4658 O
woman 9 14 4659 4664 B-gender
become 15 21 4665 4671 O
pregnant 22 30 4672 4680 B-pregnancy
or 31 33 4681 4683 O
suspect 34 41 4684 4691 O
she 42 45 4692 4695 O
is 46 48 4696 4698 O
pregnant 49 57 4699 4707 O
while 58 63 4708 4713 O
she 64 67 4714 4717 O
or 68 70 4718 4720 O
her 71 74 4721 4724 O
partner 75 82 4725 4732 O
is 83 85 4733 4735 O
participating 86 99 4736 4749 O
in 100 102 4750 4752 O
this 103 107 4753 4757 O
study 108 113 4758 4763 O
, 113 114 4763 4764 O
she 115 118 4765 4768 O
should 119 125 4769 4775 O
inform 126 132 4776 4782 O
her 133 136 4783 4786 O
treating 137 145 4787 4795 O
physician 146 155 4796 4805 O
immediately 156 167 4806 4817 O

Subjects 0 8 4818 4826 O
who 9 12 4827 4830 O
received 13 21 4831 4839 O
pemetrexed 22 32 4840 4850 B-treatment
, 32 33 4850 4851 O
bevacizumab 34 45 4852 4863 B-treatment
, 45 46 4863 4864 O
or 47 49 4865 4867 O
erlotinib 50 59 4868 4877 B-treatment
as 60 62 4878 4880 O
maintenance 63 74 4881 4892 B-treatment
therapy 75 82 4893 4900 I-treatment
( 83 84 4901 4902 O
nonprogressors 84 98 4902 4916 B-treatment
with 99 103 4917 4921 I-treatment
platinum 104 112 4922 4930 I-treatment
- 112 113 4930 4931 I-treatment
based 113 118 4931 4936 I-treatment
doublet 119 126 4937 4944 I-treatment
chemotherapy 127 139 4945 4957 I-treatment
) 139 140 4957 4958 O
and 141 144 4959 4962 O
subsequently 145 157 4963 4975 O
progressed 158 168 4976 4986 O
after 169 174 4987 4992 O
maintenance 175 186 4993 5004 O
therapy 187 194 5005 5012 O
) 194 195 5012 5013 O
are 196 199 5014 5017 O
eligible 200 208 5018 5026 O
and 209 212 5027 5030 O
do 213 215 5031 5033 O
not 216 219 5034 5037 O
count 220 225 5038 5043 O
as 226 228 5044 5046 O
a 229 230 5047 5048 O
line 231 235 5049 5053 O
of 236 238 5054 5056 O
therapy 239 246 5057 5064 O

Subjects 0 8 5065 5073 O
with 9 13 5074 5078 O
a 14 15 5079 5080 O
history 16 23 5081 5088 O
of 24 26 5089 5091 O
interstitial 27 39 5092 5104 B-chronic_disease
lung 40 44 5105 5109 I-chronic_disease
disease 45 52 5110 5117 I-chronic_disease

Subjects 0 8 5118 5126 O
with 9 13 5127 5131 O
recurrent 14 23 5132 5141 O
disease 24 31 5142 5149 O
> 32 33 5150 5151 O
6 34 35 5152 5153 B-lower_bound
months 36 42 5154 5160 I-lower_bound
after 43 48 5161 5166 O
adjuvant 49 57 5167 5175 B-treatment
or 58 60 5176 5178 I-treatment
neoadjuvant 61 72 5179 5190 I-treatment
platinum 73 81 5191 5199 I-treatment
- 81 82 5199 5200 I-treatment
based 82 87 5200 5205 I-treatment
chemotherapy 88 100 5206 5218 I-treatment
, 100 101 5218 5219 O
who 102 105 5220 5223 O
also 106 110 5224 5228 O
subsequently 111 123 5229 5241 O
progressed 124 134 5242 5252 O
during 135 141 5253 5259 O
or 142 144 5260 5262 O
after 145 150 5263 5268 O
a 151 152 5269 5270 O
platinum 153 161 5271 5279 B-treatment
- 161 162 5279 5280 I-treatment
doublet 162 169 5280 5287 I-treatment
regimen 170 177 5288 5295 I-treatment
given 178 183 5296 5301 I-treatment
to 184 186 5302 5304 I-treatment
treat 187 192 5305 5310 I-treatment
the 193 196 5311 5314 I-treatment
recurrences 197 208 5315 5326 I-treatment
, 208 209 5326 5327 O
are 210 213 5328 5331 O
eligible 214 222 5332 5340 O
and 223 226 5341 5344 O
do 227 229 5345 5347 O
not 230 233 5348 5351 O
count 234 239 5352 5357 O
as 240 242 5358 5360 O
another 243 250 5361 5368 O
line 251 255 5369 5373 O
of 256 258 5374 5376 O
therapy 259 266 5377 5384 B-treatment
for 267 270 5385 5388 I-treatment
advanced 271 279 5389 5397 I-treatment
disease 280 287 5398 5405 I-treatment

Subjects 0 8 5406 5414 O
with 9 13 5415 5419 O
vitiligo 14 22 5420 5428 B-chronic_disease
, 22 23 5428 5429 O
type 24 28 5430 5434 B-chronic_disease
1 29 30 5435 5436 I-chronic_disease
diabetes 31 39 5437 5445 I-chronic_disease
mellitus 40 48 5446 5454 I-chronic_disease
, 48 49 5454 5455 O
residual 50 58 5456 5464 O
hypothyroidism 59 73 5465 5479 B-chronic_disease
requiring 74 83 5480 5489 O
hormone 84 91 5490 5497 B-treatment
replacement 92 103 5498 5509 I-treatment
, 103 104 5509 5510 O
or 105 107 5511 5513 O
conditions 108 118 5514 5524 O
not 119 122 5525 5528 O
expected 123 131 5529 5537 O
to 132 134 5538 5540 O
recur 135 140 5541 5546 O
in 141 143 5547 5549 O
the 144 147 5550 5553 O
absence 148 155 5554 5561 O
of 156 158 5562 5564 O
an 159 161 5565 5567 O
external 162 170 5568 5576 O
trigger 171 178 5577 5584 O
are 179 182 5585 5588 O
permitted 183 192 5589 5598 O
to 193 195 5599 5601 O
enroll 196 202 5602 5608 O

The 0 3 5609 5612 O
effects 4 11 5613 5620 O
of 12 14 5621 5623 O
entinostat 15 25 5624 5634 B-treatment
, 25 26 5634 5635 O
azacitidine 27 38 5636 5647 B-treatment
, 38 39 5647 5648 O
and 40 43 5649 5652 O
Nivolumab 44 53 5653 5662 B-treatment
, 53 54 5662 5663 O
on 55 57 5664 5666 O
the 58 61 5667 5670 O
developing 62 72 5671 5681 O
human 73 78 5682 5687 O
fetus 79 84 5688 5693 O
are 85 88 5694 5697 O
unknown 89 96 5698 5705 O

Uncontrolled 0 12 5706 5718 O
inter 13 18 5719 5724 B-chronic_disease
- 18 19 5724 5725 I-chronic_disease
current 19 26 5725 5732 I-chronic_disease
illness 27 34 5733 5740 I-chronic_disease
including 35 44 5741 5750 O
, 44 45 5750 5751 O
but 46 49 5752 5755 O
not 50 53 5756 5759 O
limited 54 61 5760 5767 O
to 62 64 5768 5770 O
, 64 65 5770 5771 O
ongoing 66 73 5772 5779 O
or 74 76 5780 5782 O
active 77 83 5783 5789 B-chronic_disease
infection 84 93 5790 5799 I-chronic_disease
, 93 94 5799 5800 O
symptomatic 95 106 5801 5812 O
congestive 107 117 5813 5823 B-chronic_disease
heart 118 123 5824 5829 I-chronic_disease
failure 124 131 5830 5837 I-chronic_disease
, 131 132 5837 5838 O
unstable 133 141 5839 5847 O
angina 142 148 5848 5854 B-chronic_disease
pectoris 149 157 5855 5863 I-chronic_disease
, 157 158 5863 5864 O
cardiac 159 166 5865 5872 O
arrhythmia 167 177 5873 5883 B-chronic_disease
, 177 178 5883 5884 O
or 179 181 5885 5887 O
psychiatric 182 193 5888 5899 B-chronic_disease
illness 194 201 5900 5907 I-chronic_disease
/ 201 202 5907 5908 O
social 202 208 5908 5914 O
situations 209 219 5915 5925 O
that 220 224 5926 5930 O
would 225 230 5931 5936 O
limit 231 236 5937 5942 O
compliance 237 247 5943 5953 O
with 248 252 5954 5958 O
study 253 258 5959 5964 O
requirements 259 271 5965 5977 O

subject 0 7 5978 5985 O
who 8 11 5986 5989 O
received 12 20 5990 5998 O
a 21 22 5999 6000 O
tyrosine 23 31 6001 6009 B-treatment
kinase 32 38 6010 6016 I-treatment
inhibitor 39 48 6017 6026 I-treatment
after 49 54 6027 6032 O
failure 55 62 6033 6040 O
of 63 65 6041 6043 O
a 66 67 6044 6045 O
prior 68 73 6046 6051 B-treatment
platinum 74 82 6052 6060 I-treatment
- 82 83 6060 6061 I-treatment
based 83 88 6061 6066 I-treatment
therapy 89 96 6067 6074 I-treatment
, 96 97 6074 6075 O
that 98 102 6076 6080 O
tyrosine 103 111 6081 6089 B-treatment
kinase 112 118 6090 6096 I-treatment
inhibitor 119 128 6097 6106 I-treatment
therapy 129 136 6107 6114 I-treatment
would 137 142 6115 6120 O
count 143 148 6121 6126 O
as 149 151 6127 6129 O
an 152 154 6130 6132 O
additional 155 165 6133 6143 O
line 166 170 6144 6148 O
of 171 173 6149 6151 O
therapy 174 181 6152 6159 O

